Danish pharmaceutical powerhouse Novo Nordisk has emerged as one of the standout performers among European mega-cap stocks in the early months of this year, boasting a robust 25% surge year to date. This performance further cemented Novo Nordisk’s status as the largest European company by market capitalisation, reaching almost €550 billion and outpacing the market value of Tesla. Over the past year, the Danish pharma titan has seen its price jump by 80%, a rate of increase unmatched by any other European company valued at €100 billion or more. Novo Nordisk’s growth driver: Weight-loss drug Weg…